论文部分内容阅读
目的系统评价丹红注射液联合奥拉西坦治疗老年脑梗死疗效及安全性,为临床治疗提供循证参考。方法计算机检索Cochrane Library、Pub Med、Web of Science、中国期刊全文数据库、维普数据库、万方数据库、中国生物医学文献数据库,纳入有关丹红注射液联合奥拉西坦(治疗组)与单用丹红注射液(对照组)比较治疗老年脑梗死的随机对照试验(RCT)。根据Jadad评分量表评价纳入研究的质量,采用Cochrane协作网提供的Rev Man 5.3软件进行Meta分析。结果共纳入8个老年脑梗死RCT。Meta分析结果显示:治疗组患者治愈率[RR=1.39,95%CI(1.20,1.61),P<0.01]、有效率[RR=1.20,95%CI(1.14,1.26),P<0.01]均高于对照组,差异有统计学意义;不良反应(静脉滴注部位发红、头晕)发生率比较两组差异无统计学意义(P>0.05)。结论丹红注射液联合奥拉西坦治疗老年脑梗死的疗效优于单用丹红注射液。
Objective To evaluate the efficacy and safety of Danhong injection plus oxiracetam in the treatment of senile cerebral infarction and provide evidence-based reference for clinical treatment. Methods We searched the Cochrane Library, Pub Med, Web of Science, Chinese Journal Full-text Database, VIP Database, Wanfang Database and China Biomedical Literature Database. The data of Danhong injection combined with oxiracetam (treatment group) Red injection (control group) compared to the treatment of senile cerebral infarction randomized controlled trials (RCT). The quality of the included studies was evaluated according to the Jadad Rating Scale and Meta-analysis was performed using Rev Man 5.3 software provided by the Cochrane Collaboration. Results A total of 8 elderly patients with cerebral infarction RCT were included. The results of Meta analysis showed that the cure rate in the treatment group [RR = 1.39,95% CI (1.20,1.61), P <0.01], and the effective rate [RR = 1.20,95% CI 1.14,1.26, P <0.01] Higher than the control group, the difference was statistically significant; adverse reactions (venous drip redness, dizziness) incidence was no significant difference between the two groups (P> 0.05). Conclusion Danhong injection combined with oxiracetam in the treatment of senile cerebral infarction is better than Danhong injection alone.